American Healthcare REIT's Turnaround Is Real. The 1.67% Dividend Yield Is The Problem.

AHR posted what can only be called a strong quarter. Normalized funds from operations — the REIT earnings measure that strips out depreciation and other non-cash charges — rose 28.6% to $0.54 per share. Same-store net operating income grew 13.2%. Management raised full-year guidance. The stock surged 3.7% on the news.

That's the story the earnings press release wants you to carry forward. For an income-focused portfolio, it's the wrong story to prioritize.

Because the question that should come first isn't whether the cash-flow engine is improving. It's whether the dividend that engine produces is worth the price you're paying to own it.

The income engine is working. That's not the surprise.

AHR owns roughly 327 healthcare real estate properties — senior housing communities, skilled nursing facilities, and outpatient medical buildings — across the United States, the United Kingdom, and Ireland. The cash flow comes from two sources: resident fees in properties AHR operates directly (called SHOP — Senior Housing Operating Properties — and Trilogy integrated health campuses), and rent from triple-net leased assets where tenants handle most operating costs.

Here's what Q2 tells us about that engine:

• Same-store NOI grew 13.2% year over year, marking the tenth consecutive quarter of double-digit growth.
• Trilogy campuses delivered 16.1% same-store NOI growth at 90.7% occupancy, with margins at a post-pandemic high of 21.1%. Operating expenses actually fell 0.9% sequentially.
• SHOP properties — now the second-largest segment of the portfolio — grew same-store NOI 20.5%, with margins expanding 242 basis points to 22.3%. July leasing activity was ahead of the Q2 pace, suggesting operators have pricing power as they enter the seasonal selling period.
• Cash NOI (total operating income from the portfolio, not just same-store) grew roughly 31% year over year, helped by full-period contributions from acquisitions closed earlier this year.

This isn't a one-time bump. The demand-supply imbalance in senior housing — an aging population funneling into a market that hasn't built enough quality inventory — has sustained double-digit growth for two straight years. Management raised full-year 2026 same-store NOI guidance to 11%–13%, up from the 9%–12% range issued at the end of February.

The cash-flow story is genuinely improving. I'm not disputing that.

The dividend does what it's supposed to do — but barely.

AHR pays $0.25 per share quarterly, or $1.00 annually. At the current price near $57, that works out to a dividend yield of 1.67%. That is the number you compare against the 2-year Treasury, against other REITs, against the alternative uses for the same dollars.

The payout ratio tells the second part of the story. On a trailing-twelve-month basis, AHR's dividend payout ratio sits at 216.5%. That means the company paid out more than twice the normalized earnings it generated over the past year to fund the quarterly distribution. Free cash flow over the same period was $36.84 million, down 72.6% year over year, weighed down by $278.1 million in capital expenditures.

A 216.5% payout ratio doesn't mean the dividend is about to be cut. REIT payout ratios are structurally higher than regular companies because of how depreciation works in real estate accounting — buildings lose value on the books but may actually be appreciating in the market. What the ratio does tell you is that the dividend is funded more by capital recycling and debt capacity than by pure operating cash flow. The safety cushion isn't thick.

For context, the dividend has only been paid for one year. There is no established history of raises or cuts. The stock has appreciated roughly 40% over the past twelve months and is up 20.6% year-to-date, approaching its 52-week high of $58.70. The price does most of the work here. The dividend is an afterthought.

The valuation is where the income investor should pause.

AHR trades at a market cap of $11 billion and an enterprise value of $12.6 billion. On a trailing basis, the P/E ratio is 110x and EV/EBITDA is 30x. Those are not income-REIT multiples. They are growth-stock multiples.

Now compare that to healthcare REIT peers:

• Healthpeak (DOC) trades at 61x earnings and 15.6x EV/EBITDA — and yields 5.7%.
• Omega Healthcare (OHI) trades at 17x earnings and 16.6x EV/EBITDA — and yields 5.5%.
• W. P. Carey (WPC), a diversified REIT, trades at 25x earnings and 19.4x EV/EBITDA — and yields 5.0%.

AHR costs almost twice as much relative to earnings as Omega Healthcare, and nearly twice as much on an enterprise-value-to-EBITDA basis — while paying roughly a third of the dividend. You can tell yourself the premium is justified because AHR's same-store growth is faster than its peers'. That's a fair argument if you're optimizing for earnings growth. It's a harder argument if you're optimizing for the income that shows up in your account every quarter.

The acquisition machine is the hidden cost

AHR closed more than $1.4 billion in acquisitions year to date through June 30. Post-quarter, the company snapped up another 10 SHOP communities for roughly $1 billion, plus an $86 million loan with acquisition options. An additional $800 million pipeline sits ahead, management said, and none of it is included in the raised NFFO guidance.

That's roughly $3.3 billion in deals over a few months. Going-in yields are in the mid-5% to low-6% range, with stabilized yields of 7% or higher. The average vintage of the newest acquisitions is 2019, meaning AHR is replacing aging properties with newer assets — which is good for long-term quality but not for near-term cash flow, because these buildings will need time to absorb new residents and ramp toward stabilized operations.

Funding all of this required roughly $1.5 billion in equity raised during Q2 and post-quarter through follow-on offerings and at-the-market sales. That equity issuance dilutes existing shareholders. Your slice of the pie gets smaller even if the total pie gets bigger.

The leverage metric looks better on the surface: net debt to EBITDA improved to 2.5x in Q2, down from 3.0x in Q1 and 3.7x a year ago. That's a meaningful improvement. But total debt still sits at $2.1 billion against $119.4 million in cash. The balance sheet has room to absorb stress, but the heavy acquisition pace and equity dilution mean the per-share income picture isn't as clean as the headline NFFO growth suggests.

What this means for the income portfolio

AHR is a turnaround story dressed up as a dividend play. The operational recovery is legitimate. The senior housing fundamentals — occupancy, pricing power, margin expansion — support management's raised outlook. If the midpoint of the new NFFO guidance ($2.17) holds, that's roughly 26% earnings growth from 2025.

But a 26% NFFO growth rate at a 1.67% dividend yield means you're paying a steep price for the recovery and collecting very little income while you wait. The payout ratio, the thin free cash flow, the heavy equity dilution, and the one-year dividend history all point to a company that is growing faster than it is paying — which is fine if your goal is capital appreciation. It's less fine if your goal is a dependable quarterly check.

For income portfolios, AHR belongs in the watch list, not the core allocation. If the stock pulls back from these levels — toward the $45-$50 range where the yield would approach 2.2%-$2.3% — it becomes a more interesting reinvestment opportunity. At $57, with peers offering triple the yield on more reasonable valuation multiples, the arithmetic doesn't support adding this name to a portfolio that depends on current cash flow.

The business is getting better. The dividend isn't going anywhere at the moment. But the stock is pricing in all that improvement and then some, while handing you 1.67% to wait. If you need income now, there are healthcare REITs that will pay you three times as much to carry the same sector bet.

Portfolio action: Hold existing positions if you believe in the longer-term recovery arc. Don't add at current prices. Watch for a pullback toward $45-$50, where the yield becomes a more meaningful part of the equation. If the payout ratio doesn't compress meaningfully over the next two quarters, or if the acquisition pace slows without a corresponding rise in the dividend, the growth thesis is the only thing left holding up the stock — and growth theses don't pay bills in retirement.